Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Executive Summary

Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.

Advertisement

Related Content

Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody
Amgen's Blincyto Adds Pediatric Claim For Leukemia
Spate Of Late-Stage DLBCL Trial Failures Leaves Spoils Waiting
Amgen's Blincyto Doubles Survival In TOWER
Amgen, Merck To Test New Immunotherapy Combination
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Amgen Bets $45m Plus Up To $1.7bn On Xencor's Bi-Specifics
Amgen gains early US win for BiTE antibody Blincyto
Is The Time Finally Right For Bispecific Antibodies?
Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel